Irrimax Corporation

Irrimax Corporation is a United States-based medical device company focused on wound irrigation. It is best known as the maker of Irrisept, a self-contained jet lavage device that delivers a bottled solution containing low-concentration chlorhexidine gluconate (CHG) as a preservative. The company describes itself as a pioneer in wound irrigation, positioning Irrisept as an alternative to traditional irrigation methods. Irrimax is headquartered in Lawrenceville, Georgia, and is a wholly owned subsidiary of Innovation Technologies, Inc., which holds the rights to U.S. and worldwide patents covering the use of low-concentration CHG (less than 1%) technology. The company's flagship product, Irrisept, was introduced in 2010 and has since seen widespread adoption in the United States and internationally. Irrisept is marketed as an antimicrobial wound lavage intended for mechanical cleansing and removal of debris, dirt, and foreign materials, including microorganisms, from wounds. It is offered in a range of sizes and configurations, including 150 mL and 450 mL sterile-packaged bottles, accessory kits, and post-acute wound care configurations. The product is designed for ease of use, ready to use in seconds, and provides low-pressure or pressurized irrigation depending on the configuration. Irrimax's stated mission is to reduce infections, reduce healthcare costs, and improve patient outcomes, with a vision to become the standard of care for surgical wound irrigation. The company is led by a team of experienced medical device industry professionals. Mark Alvarez serves as Chief Executive Officer; he previously held leadership roles at BC Technical, Microtek Medical, and Recall North America. Irrimax states that it is consistently ranked among the best in its peer group for product quality, service levels, and customer support. The company operates in the medical device and advanced wound care space, selling primarily to hospitals, surgical centers, and post-acute care providers. Its product line is centered on the Irrisept brand, which includes the Irriprobe applicator, convenience caps, splatterguards, and spikeable connection kits. Irrimax emphasizes clinical evidence, including in-vivo and in-vitro studies and randomized controlled trial (RCT) data, as well as independent and third-party research supporting its product.

Irrimax Corporation was established as a medical device company focused on wound irrigation. Its flagship product, Irrisept, was introduced in 2010. According to the company, Irrisept was a patented product that provided an alternative to traditional irrigation methods, and it has since seen widespread adoption in the United States and internationally. The company describes itself as a pioneer in wound irrigation, having redefined irrigation through the introduction of this product. Irrimax is a wholly owned subsidiary of Innovation Technologies, Inc., which holds the rights to U.S. and worldwide patents that provide broad protection for the use of low-concentration chlorhexidine gluconate (less than 1%) technology. This patent portfolio underpins the Irrisept product line. The company is headquartered in Lawrenceville, Georgia, United States. It is led by a team of experienced members of the medical device industry. Mark Alvarez serves as Chief Executive Officer; he was most recently chairman, president & CEO of BC Technical, a healthcare services company focused on diagnostic imaging solutions. Prior to that, he consulted with private equity groups and served as chairman-elect & COO of Microtek Medical, a global manufacturer of custom infection control products, and president of Recall North America. Irrimax's mission is focused on reducing infections, reducing healthcare costs, and improving patient outcomes. Its vision is to become the standard of care for surgical wound irrigation. The company states that it is consistently ranked among the best in its peer group in product quality, service levels, and customer support. The Irrisept product line has expanded to include multiple sizes and configurations, such as 150 mL and 450 mL sterile-packaged bottles, accessory kits, and post-acute wound care configurations. The product is marketed for mechanical cleansing and removal of debris, dirt, and foreign materials, including microorganisms, from wounds. Irrimax emphasizes clinical evidence, including in-vivo and in-vitro studies and RCT data, as well as independent and third-party research.

• 2010

  Introduction of Irrisept, the company's flagship patented product.

Pioneer in wound irrigation offering a patented antimicrobial lavage as an alternative to traditional irrigation, aiming to become the standard of care for surgical wound irrigation.

• Irrisept Antimicrobial Wound Lavage 450 mL, Sterile Packaged

  Includes (1) 450mL bottle of Irrisept, (1) Irriprobe applicator, and (1) Convenience cap in sterile packaging. 12 bottles per case. Manufacturer #: ISEPT-450-USA.

• Irrisept Antimicrobial Wound Lavage 150 mL, Sterile Packaged

  Includes (1) 150mL bottle of Irrisept and (1) Irriprobe applicator in sterile packaging. 15 bottles per case. Manufacturer #: ISEPT-150-USA.

• Irrisept Accessory Kit Spikeable connection, Sterile Packaged

  To be connected to ISEPT-450-USA. Includes (1) Vented Spike, (1) Spikable Cap, (2) Bottle Hangers. 24 kits per case. Manufacturer #: ISEPT-AK-USA.

• Irrisept Antimicrobial Wound Lavage 150 mL, Post Acute Wound Care

  Includes (1) 150mL bottle of Irrisept with (1) attachable Splatterguard in an easy-to-store shelf carton. 15 bottles per case. Manufacturer #: ISEPT-150N-USA.

1. 1Home - Irriseptirrisept.com
2. 2About - Irriseptirrisept.com
3. 3Products - Irriseptirrisept.com
4. 4Irrimax Corporation (United States) - Wikidatawikidata.org